Clinical significance of fibrinogen classification in esophageal cancer patients receiving neoadjuvant treatment

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Satoru Matsuda

Citation

Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523

Authors

S. Matsuda, H. Takeuchi, H. Kawakubo, K. Fukuda, R. Nakamura, T. Takahashi, N. Wada, Y. Kitagawa

Author affiliations

  • Surgery, Keio University School of Medicine, 160-8582 - Tokyo/JP
More

Resources

Aim/Background

We previously reported that fibrinogen (FNG) classification, which was based on the preoperative plasma FNG level (preop FNG) and change of FNG between pretreatment (preTx FNG) and preop FNG, could be a predictive marker of postoperative recurrence in esophageal cancer patients who received neoadjuvant chemotherapy (NAC). (Matsuda S, et al. Dis Esophagus. 2013). Currently, we conducted the follow up analysis in expanded data set and investigated the correlation with overall survival.

Methods

We retrospectively reviewed 178 patients who underwent transthoracic esophagectomy after NAC between 2000 and 2014. PreTx and preop FNG were confirmed in 132 patients. FNG classification was defined as previous report; based on preTx and preop FNG, patients in which FNG decreased during NAC and preop FNG < 350mg/dl was classified as Class A, either FNG increased during NAC or pre-op FNG > 350mg/dl as Class B, and both FNG increased and preop FNG > 350m/dl as Class C. The correlation between FNG classification, clinicopathological factors, recurrence free survival (RFS), and overall survival (OS) was investigated.

Results

In 132 patients, distribution of pretreatment clinical stage was cStage I/II/III/IV of 21/34/70/7 respectively. The number of patients for each FNG classification Class A/B/C was 42/55/35. Tumor depth was significantly progressed in Class C (cT1/2/3/4, Class A 4/12/17/9, Class B 6/20/28/1, Class C 2/6/25/2. P = 0.007). In survival multivariate analysis in which cStage was used as a covariate, FNG classification was shown to be a predictive factor for RFS independent of cStage significantly (Class B: HR, 2.277; P = 0.018; Class C: HR, 2.498; P = 0.013). Regarding the OS, Class C was evaluated as a significant factor of poor survival (Class B: HR, 1.858; P = 0.106; Class C: HR, 2.307; P = 0.037).

Conclusions

FNG classification was shown to predict postoperative recurrence independent of cStage in this study. In order to confirm the benefit in the OS, further follow up is necessary. Fibrinogen is a popular indicator routinely measured in daily practice, FNG classification may be validate and feasible in esophageal cancer patients who received neoadjuvant chemotherapy.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings